Epizyme, Inc. is a Cambridge, MA-based development-stage biopharmaceutical company focused on bringing novel epigenetic oncology therapies to the market.
Being a development-stage company, Epizyme does not have any approved product in its portfolio yet. Hence, investor focus should remain on pipeline updates.
Epizyme’s lead candidate, tazemetostat (an EZH2 inhibitor) is being evaluated in phase II studies in non-Hodgkin lymphoma (NHL) and genetically defined solid tumors. Epizyme has planned to report efficiency, safety and biomarker data from both studies in the first half of 2017.
The company’s track record has been strong, with the company beating estimates in three of the last four quarters and missing on one occasion, with an average positive earnings surprise of 7.32%.
Currently, Epizyme has a Zacks Rank # 3 (Hold), but that could definitely change following the company’s earnings report which was just released. We have highlighted some of the key stats from this just-revealed announcement below:
Earnings:Epizyme posted narrower-than-expected loss in the third quarter of 2016. While our consensus called for a loss of 56 cents per share, the company reported a loss of 42 cents.
Revenues: The company reported collaboration revenues of $6.6 million compared to the Zacks Consensus Estimate of 0.57 million .
Key Stats:The company said that it has initiated a front-line phase Ib/II study on tazemetostat in combination with R-CHOP, the standard-of-care chemotherapy regimen for patients with newly diagnosed diffuse large B cell lymphoma (DLBCL).
Share Price Impact:Inactive in pre-market trading.
Check back later for our full write up on EPZM earnings report later!
Confidential from Zacks
Beyond this Tale of the Tape, would you like to see Zacks' best recommendations that are not available to the public? Our Executive VP, Steve Reitmeister, knows when key trades are about to be triggered and which of our experts has the hottest hand. Click to see them now>>
Zacks Names "Single Best Pick to Double"
From thousands of stocks, 5 Zacks experts each have chosen their favorite to skyrocket +100% or more in months to come. From those 5, Director of Research Sheraz Mian hand-picks one to have the most explosive upside of all.
It’s a little-known chemical company that’s up 65% over last year, yet still dirt cheap. With unrelenting demand, soaring 2022 earnings estimates, and $1.5 billion for repurchasing shares, retail investors could jump in at any time.
This company could rival or surpass other recent Zacks’ Stocks Set to Double like Boston Beer Company which shot up +143.0% in little more than 9 months and NVIDIA which boomed +175.9% in one year.
Free: See Our Top Stock and 4 Runners Up >>
Epizyme, Inc. is a Cambridge, MA-based development-stage biopharmaceutical company focused on bringing novel epigenetic oncology therapies to the market.
Being a development-stage company, Epizyme does not have any approved product in its portfolio yet. Hence, investor focus should remain on pipeline updates.
Epizyme’s lead candidate, tazemetostat (an EZH2 inhibitor) is being evaluated in phase II studies in non-Hodgkin lymphoma (NHL) and genetically defined solid tumors. Epizyme has planned to report efficiency, safety and biomarker data from both studies in the first half of 2017.
The company’s track record has been strong, with the company beating estimates in three of the last four quarters and missing on one occasion, with an average positive earnings surprise of 7.32%.
Currently, Epizyme has a Zacks Rank # 3 (Hold), but that could definitely change following the company’s earnings report which was just released. We have highlighted some of the key stats from this just-revealed announcement below:
Earnings:Epizyme posted narrower-than-expected loss in the third quarter of 2016. While our consensus called for a loss of 56 cents per share, the company reported a loss of 42 cents.
Revenues: The company reported collaboration revenues of $6.6 million compared to the Zacks Consensus Estimate of 0.57 million .
Key Stats:The company said that it has initiated a front-line phase Ib/II study on tazemetostat in combination with R-CHOP, the standard-of-care chemotherapy regimen for patients with newly diagnosed diffuse large B cell lymphoma (DLBCL).
Share Price Impact:Inactive in pre-market trading.
Check back later for our full write up on EPZM earnings report later!
Confidential from Zacks
Beyond this Tale of the Tape, would you like to see Zacks' best recommendations that are not available to the public? Our Executive VP, Steve Reitmeister, knows when key trades are about to be triggered and which of our experts has the hottest hand. Click to see them now>>
Zacks Names "Single Best Pick to Double"
From thousands of stocks, 5 Zacks experts each have chosen their favorite to skyrocket +100% or more in months to come. From those 5, Director of Research Sheraz Mian hand-picks one to have the most explosive upside of all.
It’s a little-known chemical company that’s up 65% over last year, yet still dirt cheap. With unrelenting demand, soaring 2022 earnings estimates, and $1.5 billion for repurchasing shares, retail investors could jump in at any time.
This company could rival or surpass other recent Zacks’ Stocks Set to Double like Boston Beer Company which shot up +143.0% in little more than 9 months and NVIDIA which boomed +175.9% in one year.
Free: See Our Top Stock and 4 Runners Up >>